Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Bone tumor burden is significantly lower and the number of bone metastases/mouse is significantly inhibited
704869-38-5
CAS Number: 1173022-16-6
Exposure of proliferating WS1 cells to MK-8776 S-isomer is associated with rapid
Ambrisentan 1267 Bone tumor burden is significantlyAmbrisentan, also known as BSF 208075 and LU 208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6 minute walk distance) compared with placebo in two double blind, multicenter trials (ARIES 1 and ARIES 2). Ambrisentan was approved by
US$ 20.00
US$ 100.00
US$ 49.00